| This week's sponsor is Premier Research. | | | >From Lab to Bedside: The Latest in Rare Oncology Drug Research
Study of rare cancers demands immersion in dual indications where strategies often don't mesh. Attend our Feb. 28 webinar for fresh insights on speeding development of new drugs. Register now. Premier Research. It's what we do. Best. |
| | | Daiichi, ArQule’s struggling tivantinib fails in phase 3 liver cancer test Sage Therapeutics fuels, then dampens, its own M&A rumors British investment firm Arix Bioscience hits £100M IPO target [Sponsored] Mitotech eyes novel approach to treating Dry Eye Disease Trial shows ArmaGen biologic improves cognition in Hurler syndrome patients Gilead sells phase 2 addiction drug to ex-CVT team Takeda, TiGenix stem cell therapy shows sustained effect EuroBiotech Report: NASH IPO, uniQure trials, Kitov fraud allegations, Ferring-Foresee and cancer stem cell pact FiercePharmaAsia: PRA and Takeda’s Japan JV, Sun’s shrunken profits, ASLAN’s positive varlitinib data Chutes & Ladders: J&J vet Bridget Ross jumps ship to Henry Schein Publisher's Note: FierceBiotech will not be publishing Monday, Feb. 20, in recognition of Presidents Day. We will resume our normal publishing schedule on Tuesday, Feb. 21. | |
|
Featured Story Friday, February 17, 2017 After fluffing its lines in two mid-to-late stage trials in lung and colorectal cancer over the past few years, Daiichi and ArQule had hoped that tivantinib could produce the goods in a phase 3 liver cancer test, but it was not to be.
| This week's sponsor is Charles River. | | Webinar: When to Add PDX Models into Your Oncology Program: IO and non-IO?
Could PDX be the most cost-effective tool for targeted therapies in cancer? How can PDX be incorporated into an immuno-oncology program? Can clinical biomarkers be identified using these models?
Just a few of the questions that we'll discuss in our upcoming webinar providing an overview of our extensive experience with PDX models and best ways to use in your preclinical strategy. Join us. |
Top Stories Friday, February 17, 2017 In an interview with Bloomberg published yesterday, Sage’s CEO Jeff Jonas was quoted as saying his company was at the top of everyone’s buying list, sending its shares jumping. But a few short hours later (and just before the end of after-hours trading), the chief rowed back on the M&A talk. Friday, February 17, 2017 Arix Biosciences has made good on its promise to raise £100 million ($127 million) in its public offering on the London Stock Exchange as it looks to put the new funds to use in investments across as many as 15 early-stage biotechs. Monday, February 13, 2017 An aging population, an ever increasing amount of time viewing digital devices and a growing trend in eye diseases are all factors expected to fuel a global increase in Dry Eye Disease. Friday, February 17, 2017 The biotech's CEO says the clinical trial is the first to show that it is possible to usher large-molecule drugs across the blood-brain barrier. Friday, February 17, 2017 Gilead has sold a phase 2-ready addiction candidate to Amygdala Neurosciences. The deal returns control of the ALDH2 inhibitor to the team that was developing the asset before Gilead acquired it in its $1.4 billion takeover of CV Therapeutics. Friday, February 17, 2017 Takeda and TiGenix have presented 52-week data on their allogeneic expanded adipose-derived stem cells in Crohn’s disease patients with treatment-refractory complex perianal fistulas. The data show the Cx601 stem cells continue to outperform placebo one year after administration. Thursday, February 16, 2017 In this week's EuroBiotech Report, Inventiva IPO raises €48 million for NASH trial, uniQure plots trial plan, Kitov talks fraud allegations and more. Friday, February 17, 2017 In this week's FiercePharmaAsia wrapup, PRA Health Sciences and Takeda are joining forces to build a new business in Japan, Sun's quarterly profits dropped by 5% and ASLAN's varlitinib-capecitabine combo beat the Tykerb-chemo duo in treating breast cancer as top-line phase 2 data show. Thursday, February 16, 2017 Bridget Ross has left Johnson & Johnson's medical devices business to take leadership at Henry Shein's Global Medical Group, House Energy and Commerce Committee’s majority staff director Gary Andres joins BIO and Infinity Pharma has promoted Jeffery Kutok to CSO. Plus more hirings, firings and retirings throughout the industry. | This week's sponsor is Destination Medical Center. | | | Destination Medical Center (DMC) is a 20-year, $5.6 billion economic development plan set to transform Rochester, MN. DMC and Mayo Clinic are accelerating new advancements in life science research, medical technology, patient care, and education. |
| | | Celgene has hit its testing targets in the first phase 3 for its MS candidate ozanimod. Release Heat Biologics has posted phase 2 data from vesigenurtacel-L in certain bladder cancer patients, saying that when in combo with BCG this "strengthens support for the vaccine mechanism of action and clinical proof-of-concept of immune activation." Release Catabasis Pharmaceuticals has promoted Ted Hibben to chief business officer. Release | |
|
Resources Sponsored By: Veeva Learn over a dozen best practices for deploying a global content system. Read Whitepaper. Sponsored By: Veeva Gartner provides insightful research on preparing for IDMP compliance. Read Whitepaper. Sponsored By: Veeva Learn How to Create a Unified RIM Environment for IDMP. Find out. Sponsored By: Veeva The largest survey of TMF owners reveals drivers and trends in improving inspection readiness and shortening trial time. Sponsored By: Salesforce Learn how the healthcare and life science industry is using agile application development to drive innovation and accelerate their business with the Salesforce Platform. Presented by: Patheon Can you avoid a risky trial-and-error approach to find the right path for your poorly soluble molecule by utilizing a CDMO? Download this complimentary Whitepaper to learn more! Drug Development Boot Camp® 2017 November 15-16, 2017 | Boston, MA |
